The novel tetrahydropyrimidine derivative as inhibitor of SARS CoV-2: synthesis, modeling and molecular docking analysis
| dc.contributor.author | Genc, Zuhal Karagoz | |
| dc.contributor.author | Genc, Murat | |
| dc.contributor.author | Cosut, Bunyemin | |
| dc.contributor.author | Turgut, Mehmet | |
| dc.date.accessioned | 2025-10-29T11:17:09Z | |
| dc.date.issued | 2022 | |
| dc.department | Fakülteler, Temel Bilimler Fakültesi, Kimya Bölümü | |
| dc.description.abstract | N-(1,3-Benzothiazol-2-yl)-N-(1,4,5,6-tetrahydro-1H-pyrimidine-2-yl) amine was synthesized and characterized by elemental analysis, FT-IR, NMR and X-ray single crystal diffraction. The compound structure belongs to the triclinic system with the P-1 space group with unit cell parameters a = 11.9290(4), b = 13.2547(4) and c = 15.3904(5) A. Hirhsfeld surface analysis is performed to revealintermolecular interactions with these interactions. The molecular structure, vibrational spectroscopic data and HOMOs and LUMOs analyses were calculated by using the DFT/B3LYP method with the 6-311thornG(d,p)) basis set. Some of pharmacokinetic parameters and drug-likeness properties of the compound were also performed. Besides these, the present work is a searching to test N-(1,3-benzothiazol-2-yl)-N-(1,4,5,6-tetrahydro-1H-pyrimidine-2-yl) amine as an inhibitor for the SARS-CoV-2. For this aim, the molecular docking analysis of the synthesized compound was applied along with Favipiravir. Besides the docking results, ADMET properties of the compound were also calculated. | |
| dc.identifier.doi | 10.1080/07391102.2021.1938230 | |
| dc.identifier.endpage | 10056 | |
| dc.identifier.issn | 0739-1102 | |
| dc.identifier.issn | 1538-0254 | |
| dc.identifier.issue | 20 | |
| dc.identifier.pmid | 34180374 | |
| dc.identifier.scopus | 2-s2.0-85144245365 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 10045 | |
| dc.identifier.uri | https://doi.org/10.1080/07391102.2021.1938230 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14854/7935 | |
| dc.identifier.volume | 40 | |
| dc.identifier.wos | WOS:000667101200001 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis Inc | |
| dc.relation.ispartof | Journal of Biomolecular Structure & Dynamics | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WOS_20251020 | |
| dc.subject | Tetrahydropyrimidine | |
| dc.subject | DFT/ B3LYP | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | ADMET | |
| dc.subject | Drug-likeness | |
| dc.title | The novel tetrahydropyrimidine derivative as inhibitor of SARS CoV-2: synthesis, modeling and molecular docking analysis | |
| dc.type | Article |








